Key result
While overall pharmacological prophylaxis was associated with a higher rate of venous thromboembolism compared to no prophylaxis (1.77% vs 1.19%, OR 1.50) likely due to confounding by indication, rivaroxaban significantly reduced VTE incidence following total knee arthroplasty (OR 0.72).
Why the study?
Does pharmacological thromboprophylaxis reduce venous thromboembolism in Korean patients undergoing total knee or hip arthroplasty?
Population
306,912 Korean patients who underwent total knee arthroplasty or total hip arthroplasty between 2009 and…
Comparison
Pharmacological thromboprophylaxis administered… vs No pharmacological thromboprophylaxis.
Design
Cohort
Follow-up
3 months
Authors
Loading...
Suggests rivaroxaban may offer targeted VTE protection in low-risk Asian populations following.
Observational (n=306,912)
Yes
Does pharmacological thromboprophylaxis reduce venous thromboembolism in Korean patients undergoing total knee or hip arthroplasty?
Odds Ratio: 1.5 (95% CI 1.41–1.6)
Absolute Event Rate: 1.77% vs 1.19%
In a Korean population with a low baseline risk of VTE, pharmacological thromboprophylaxis (specifically rivaroxaban or duration ≥10 days) can further reduce VTE incidence after TKA, despite an overall increase in red blood cell transfusions.
Yhim et al. (2017) conducted an observational in Total knee and hip arthroplasty (n=306,912). Pharmacological thromboprophylaxis vs. No pharmacological prophylaxis was evaluated on Incidence of venous thromboembolism (VTE) within 3 months of surgery (OR 1.50, 95% CI 1.41-1.60). While overall pharmacological prophylaxis was associated with a higher rate of venous thromboembolism compared to no prophylaxis (1.77% vs 1.19%, OR 1.50) likely due to confounding by indication, rivaroxaban significantly reduced VTE incidence following total knee arthroplasty (OR 0.72).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: